{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=112",
    "query": {
      "condition": "Mouth Disease",
      "page": 112
    },
    "page_size": 10
  },
  "pagination": {
    "page": 112,
    "page_size": 10,
    "total_count": 5936,
    "total_pages": 594,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=113&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=111&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:04:25.766Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02177591",
      "title": "Observational Study of the Association Between Periodontal Disease and Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Periodontal Disease",
        "Coronary Artery Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Texas Tech University Health Sciences Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 75,
      "start_date": "2014-06",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02177591"
    },
    {
      "nct_id": "NCT07812090",
      "title": "A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)"
      ],
      "interventions": [
        {
          "name": "Oral BGE-102",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo Matching BGE-102",
          "type": "DRUG"
        },
        {
          "name": "Anti-VEGF",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "BioAge Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 180,
      "start_date": "2026-08-21",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 16,
      "location_summary": "Bakersfield, California • Glendale, California • Mountain View, California + 13 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07812090"
    },
    {
      "nct_id": "NCT01786668",
      "title": "Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ankylosing Spondylitis"
      ],
      "interventions": [
        {
          "name": "Tofacitinib 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2013-04",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-10",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 22,
      "location_summary": "Indian Wells, California • Palm Desert, California • Clearwater, Florida + 15 more",
      "locations": [
        {
          "city": "Indian Wells",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01786668"
    },
    {
      "nct_id": "NCT01885208",
      "title": "Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "semaglutide",
          "type": "DRUG"
        },
        {
          "name": "exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 813,
      "start_date": "2013-12-02",
      "completion_date": "2015-07-13",
      "has_results": true,
      "last_update_posted_date": "2019-06-13",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 76,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 61 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885208"
    },
    {
      "nct_id": "NCT04870840",
      "title": "Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Head and Neck Squamous Cell Carcinoma",
        "Locally Advanced Hypopharyngeal Squamous Cell Carcinoma",
        "Locally Advanced Laryngeal Squamous Cell Carcinoma",
        "Locally Advanced Nasopharyngeal Squamous Cell Carcinoma",
        "Locally Advanced Oral Cavity Squamous Cell Carcinoma",
        "Locally Advanced Oropharyngeal Squamous Cell Carcinoma",
        "Malignant Posterior Tongue Neoplasm",
        "Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage II Hypopharyngeal Carcinoma AJCC v8",
        "Stage II Laryngeal Cancer AJCC v8",
        "Stage II Nasopharyngeal Carcinoma AJCC v8",
        "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage III Hypopharyngeal Carcinoma AJCC v8",
        "Stage III Laryngeal Cancer AJCC v8",
        "Stage III Nasopharyngeal Carcinoma AJCC v8",
        "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Proton Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-10-19",
      "completion_date": "2023-07-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04870840"
    },
    {
      "nct_id": "NCT02013050",
      "title": "A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Mucositis"
      ],
      "interventions": [
        {
          "name": "SGX942",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soligenix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2013-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-08-28",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013050"
    },
    {
      "nct_id": "NCT03975790",
      "title": "Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 479,
      "start_date": "2018-05-29",
      "completion_date": "2018-10-02",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03975790"
    },
    {
      "nct_id": "NCT02906917",
      "title": "A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin degludec/insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 532,
      "start_date": "2016-09-20",
      "completion_date": "2017-12-24",
      "has_results": true,
      "last_update_posted_date": "2019-11-13",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 30,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 26 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02906917"
    },
    {
      "nct_id": "NCT03262740",
      "title": "The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "BMS-986195",
          "type": "DRUG"
        },
        {
          "name": "Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2017-09-11",
      "completion_date": "2018-01-30",
      "has_results": false,
      "last_update_posted_date": "2020-03-20",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 2,
      "location_summary": "South Miami, Florida • Salt Lake City, Utah",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03262740"
    },
    {
      "nct_id": "NCT03692325",
      "title": "Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukoplakia, Oral"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2018-12-05",
      "completion_date": "2024-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-11-19T05:04:25.766Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03692325"
    }
  ]
}